Patents by Inventor Bernard Lerer

Bernard Lerer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Type III deiodinase inhibitors and uses thereof
    Patent number: 11091434
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: August 17, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
  • TYPE III DEIODINASE INHIBITORS AND USES THEREOF
    Publication number: 20190389799
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Application
    Filed: August 28, 2019
    Publication date: December 26, 2019
    Inventors: Bernard LERER, Mugesh GOVINDASAMY, Tzuri LIFSCHYTZ
  • Type III deiodinase inhibitors and uses thereof
    Patent number: 10435365
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 8, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard Lerer, Mugesh Govindasamy, Tzuri Lifschytz
  • TYPE III DEIODINASE INHIBITORS AND USES THEREOF
    Publication number: 20180215709
    Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
    Type: Application
    Filed: March 16, 2015
    Publication date: August 2, 2018
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., INDIAN INSTITUTE OF SCIENCE
    Inventors: Bernard LERER, Mugesh GOVINDASAMY, Tzuri LIFSCHYTZ
  • RGS2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
    Patent number: 8986929
    Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: March 24, 2015
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Bernard Lerer, Lior Greenbaum
  • ANTIPSYCHOTIC-INDUCED PARKINSONISM GENOTYPES AND METHODS OF USING SAME
    Publication number: 20130078637
    Abstract: The present invention relates to genotypes associated with resistance to antipsychotic-induced parkinsonism and other extrapyramidal symptoms induced by antipsychotics, and use of said genotypes for assessment of patient populations. The methods and kits of the invention are based on identifying in a sample obtained from a subject, specific SNPs in the ZFPM2 and RGS2 genes.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 28, 2013
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Bernard Lerer, Lior Greenbaum, Anna Alkelai
  • RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTIC MEDICATION
    Publication number: 20110236896
    Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
    Type: Application
    Filed: June 7, 2011
    Publication date: September 29, 2011
    Inventors: Bernard Lerer, Lior Greenbaum
  • RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTIC MEDICATION
    Publication number: 20100021891
    Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
    Type: Application
    Filed: June 12, 2007
    Publication date: January 28, 2010
    Inventors: Bernard Lerer, Lior Greenbaum
  • SCHIZOPHRENIA ASSOCIATED GENES AND MARKERS
    Publication number: 20090305246
    Abstract: The invention discloses schizophrenia-associated polymorphism located on chromosome 6q23 within the human Abelson Helper Integration Site 1 gene (AHI1), or a genomic region linked to the AHI1 gene that includes the C6orf217 gene. The invention further discloses systems and methods for diagnosing schizophrenia or predisposition to schizophrenia.
    Type: Application
    Filed: October 17, 2006
    Publication date: December 10, 2009
    Inventors: Bernard Lerer, Daniela Zalcenstein, Kyra Kanyas